Home/Pipeline/INV-202 (Oral)

INV-202 (Oral)

Prurigo Nodularis

Phase 2bActive

Key Facts

Indication

Prurigo Nodularis

Phase

Phase 2b

Status

Active

Company

Indivior

About Indivior

Indivior is a publicly traded, revenue-generating biopharmaceutical company dedicated to addressing substance use disorders and serious mental illnesses. A pioneer in addiction medicine, its strategy is anchored by its market-leading SUBLOCADE® (monthly buprenorphine injection) and a pipeline extending its long-acting platform into schizophrenia and depression. The company faces significant risks from ongoing legal liabilities, generic competition, and pipeline execution, but its U.S. relocation, focused commercial execution, and potential new product launches provide a pathway for sustained growth in a critical therapeutic area.

View full company profile

Therapeutic Areas

Substance Use Disorder Opioid Use Disorder Schizophrenia Mental Illness

Other Prurigo Nodularis Drugs

Drug	Company	Phase	Status
Nemolizumab	Galderma Group	Approved/Filed	Active - Launched/Under Review
SGT-610	Sol-Gel Technologies	Phase 2	Active